Croívalve secures $27M for Duo Adapt tricuspid device
· shani alexander
AI Briefing
- • Croívalve Ltd. secures $20M in series B financing for Duo Adapt tricuspid device.
- • Additional $7M secured from European Innovation Council and Disruptive Technologies Innovation Fund.
- • Funds to be used for expanding clinical study of Duo Adapt system.
Source Summary
Croívalve Ltd. secured a further $20 million in series B financing for its Duo Adapt system, a transcatheter device that treats tricuspid regurgitation. The company also received $7 million from the European Innovation Council and the Disruptive Technologies Innovation Fund in grant financing. Croívalve will use the funds to expand its clinical study, which is evaluating the safety and performance of the Duo Adapt system in patients with severe or greater symptomatic tricuspid regurgitation.
Advertisement